検索結果

g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...

Overseas Activities | SENJU Pharmaceutical

nd pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the era o...

製品開発方針 | 研究開発活動 | 千寿製薬株式会社

開発に挑戦し続けています。  #1:井上 佐智子, 川島 素子, 坪田 一男：ドライアイとは？原因から最新の治療まで、ファルマシア, 2014 50(3): 201-6  #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...

Overseas Activities | SENJU Pharmaceutical

nd pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we enter the era o...

产品开发方针 | 研究与开发 | 千寿制药株式会社

发，从而为患者带去希望。  #1: 井上 佐智子, 川岛 素子, 坪田 一男：什么是干眼症？从原因到最新的治疗，Farumashia，2014 50(3): 201-6  #2: Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254-6...